Review





Similar Products

pathway components  (Shanghai Korain Biotech Co Ltd)
93
Shanghai Korain Biotech Co Ltd pathway components
Pathway Components, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pathway components/product/Shanghai Korain Biotech Co Ltd
Average 93 stars, based on 1 article reviews
pathway components - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
components  (MedChemExpress)
96
MedChemExpress components
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Components, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/components/product/MedChemExpress
Average 96 stars, based on 1 article reviews
components - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
components  (Fuzheng Pharmaceutical Co Ltd)
86
Fuzheng Pharmaceutical Co Ltd components
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Components, supplied by Fuzheng Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/components/product/Fuzheng Pharmaceutical Co Ltd
Average 86 stars, based on 1 article reviews
components - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
onlay components  (Stryker)
86
Stryker onlay components
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Onlay Components, supplied by Stryker, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/onlay components/product/Stryker
Average 86 stars, based on 1 article reviews
onlay components - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
inlay components  (Stryker)
86
Stryker inlay components
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Inlay Components, supplied by Stryker, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inlay components/product/Stryker
Average 86 stars, based on 1 article reviews
inlay components - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
c9 1 200 novus biologicals nbp2 15952  (Novus Biologicals)
86
Novus Biologicals c9 1 200 novus biologicals nbp2 15952
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
C9 1 200 Novus Biologicals Nbp2 15952, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c9 1 200 novus biologicals nbp2 15952/product/Novus Biologicals
Average 86 stars, based on 1 article reviews
c9 1 200 novus biologicals nbp2 15952 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
component platinum ii meso tetrakis pen tafluorophenyl porphyrin pttfpp  (Frontier Specialty Chemicals Inc)
95
Frontier Specialty Chemicals Inc component platinum ii meso tetrakis pen tafluorophenyl porphyrin pttfpp
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Component Platinum Ii Meso Tetrakis Pen Tafluorophenyl Porphyrin Pttfpp, supplied by Frontier Specialty Chemicals Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/component platinum ii meso tetrakis pen tafluorophenyl porphyrin pttfpp/product/Frontier Specialty Chemicals Inc
Average 95 stars, based on 1 article reviews
component platinum ii meso tetrakis pen tafluorophenyl porphyrin pttfpp - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
xtension component  (Oxford Instruments)
99
Oxford Instruments xtension component
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Xtension Component, supplied by Oxford Instruments, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/xtension component/product/Oxford Instruments
Average 99 stars, based on 1 article reviews
xtension component - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
components components anionic surfactant  (Dow Chemical)
86
Dow Chemical components components anionic surfactant
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Components Components Anionic Surfactant, supplied by Dow Chemical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/components components anionic surfactant/product/Dow Chemical
Average 86 stars, based on 1 article reviews
components components anionic surfactant - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
molecular weight components g mol amount  (Croda International Plc)
99
Croda International Plc molecular weight components g mol amount
A) Chemical structures of lipid <t>components</t> used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.
Molecular Weight Components G Mol Amount, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/molecular weight components g mol amount/product/Croda International Plc
Average 99 stars, based on 1 article reviews
molecular weight components g mol amount - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

Image Search Results


A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

Journal: bioRxiv

Article Title: Systemic delivery of CRISPR-Cas9 nickase suppresses oncogene amplified cancer progression

doi: 10.64898/2026.04.26.720919

Figure Lengend Snippet: A) Chemical structures of lipid components used to generate LNPs for the delivery of mRNA, including ionizable cationic lipids DLin-MC3-DMA and 306-O12B, permanently cationic lipid DOTAP, helper phospholipids DSPC and DOPC, cholesterol, and DMG-PEG 2000 . Images were adapted from Cayman Chemical for noncommercial reference. B) Experimental design to assess the passive targeting of LNP formulations to the orthotopically engrafted SK-N-BE(2)C tumor and other organs. C) Representative in vivo bioluminescence image of orthotopically engrafted mice 12-days post-engraftment. D) Representative ex vivo bioluminescence image of mouse organs 24-hours post-delivery of LNPs encapsulating GLuc mRNA. Top row (left to right): liver, tumor, contralateral kidney. Bottom row (left to right): heart, lungs, spleen. E – F) Normalized BLI of each organ treatment group to the BLI of all organs combined (E) and organ-specific BLI of each treatment group relative to a vehicle-only organ control (F) as determined by ex vivo bioluminescence imaging of mouse organs at 24-hours post-delivery of DLin-MC3-DMA (n = 5 mice), 306-O12B (n = 3 mice), and DOTAP (n = 6 mice) LNPs encapsulating GLuc mRNA (3 mg/kg), where each group is baseline-corrected to a vehicle only control (n = 6 mice) and the mean of the population is indicated as a line.

Article Snippet: The following components were purchased from MedChemExpress; DLin-MC3-DMA (HY-112251), DOTAP (HY-112754A), 306-O12B (HY-W590532), DMG-PEG 2000 (HY-112764), DOPC (HY-113424A), and DSPE-PEG-Maleimide (HY-140740).

Techniques: In Vivo, Ex Vivo, Control, Imaging